These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 1626611)

  • 21. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K; Fischer C; Klotz U; Heinkel K
    Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of inflammatory bowel disease: safety and tolerability issues.
    Navarro F; Hanauer SB
    Am J Gastroenterol; 2003 Dec; 98(12 Suppl):S18-23. PubMed ID: 14697914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sulfasalazine and new analogues in inflammatory bowel disease, with focus on Crohn's disease.
    van Hees PA
    Acta Gastroenterol Belg; 1987; 50(5):555-9. PubMed ID: 2902723
    [No Abstract]   [Full Text] [Related]  

  • 24. New therapeutic agents in the treatment of inflammatory bowel disease.
    Geier DL; Miner PB
    Am J Med; 1992 Aug; 93(2):199-208. PubMed ID: 1497017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing therapy for inflammatory bowel disease.
    Robinson M
    Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study.
    Munk EM; Pedersen L; Floyd A; Nørgård B; Rasmussen HH; Sørensen HT
    Am J Gastroenterol; 2004 May; 99(5):884-8. PubMed ID: 15128355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW; Gales BJ
    Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New treatments of hemorrhagic rectocolitis].
    Rambaud JC
    Ann Gastroenterol Hepatol (Paris); 1988; 24(4):173-7. PubMed ID: 2901821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid].
    Schölmerich J; Gerok W
    Wien Klin Wochenschr; 1986 Nov; 98(22):762-9. PubMed ID: 2880425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
    Habal FM; Greenberg GR
    Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative tolerability of treatments for inflammatory bowel disease.
    Stein RB; Hanauer SB
    Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical treatment of ulcerative colitis.
    Sutherland LR
    Med Clin North Am; 1990 Jan; 74(1):119-31. PubMed ID: 1967326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical therapy for ulcerative colitis in childhood.
    Ament ME; Vargas JH
    Semin Pediatr Surg; 1994 Feb; 3(1):28-32. PubMed ID: 7914811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
    Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
    Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aminosalicylates in the treatment of inflammatory bowel disease.
    Sutherland LR
    Inflamm Bowel Dis; 1998 May; 4(2):113. PubMed ID: 9687217
    [No Abstract]   [Full Text] [Related]  

  • 38. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
    Robinson MG
    Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
    Brogden RN; Sorkin EM
    Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.